A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
SAN FRANCISCO — The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings. Patients treated with the immune checkpoint inhibitor (ICI) had a 38% reduced risk of death compared to patients on placebo, reported Tony Choueiri, MD, […]